-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutetium Lu 177 Oxodotreotide in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Oxodotreotide in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutetium Lu 177 Oxodotreotide in Neuroendocrine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SHRA-1904 in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SHRA-1904 in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SHRA-1904 in Gastroesophageal (GE) Junction Carcinomas Drug Details: SHRA-1904...
-
Product Insights
Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) - Drugs In Development, 2023’, provides an overview of the Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Neuroendocrine Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroendocrine Cancer - Drugs In Development, 2023’, provides an overview of the Neuroendocrine Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Spebrutinib Besylate in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Spebrutinib Besylate in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Spebrutinib Besylate in Diffuse Large B-Cell Lymphoma Drug Details:...
-
Track & Monitor
Venture Capital Investments Q3 2023
GlobalData's Venture Capital Investments report provides detailed coverage of the global venture capital investment activity across sectors in Q3 2023, covering key insights and trends.